Opus Genetics Inc (IRD) - News Archive

In a pioneering move in the field of ophthalmic gene therapy, Opus Genetics has achieved a significant milestone by dosing the first participant in its OPGx-BEST1 Phase 1/2 clinical trial aimed at treating Best Disease,...

RESEARCH TRIANGLE PARK, N.C. March 21, 2025 In a noteworthy advancement in the realm of ophthalmic medicine, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company that specializes in the development...

The field of ocular gene therapies has seen significant advancements in recent years, particularly for retinopathies such as Leber Congenital Amaurosis (LCA), a severe inherited retinal dystrophy. Opus Genetics has unve...

Exploring the Journey of APX3330 in Diabetic Retinopathy: A New Horizon in Ophthalmic Treatment Diabetic retinopathy is a prevalent microvascular complication of diabetes, often leading to vision impairment or loss. Tre...